What diabetes medications are safe for a patient with heart failure and chronic kidney disease, aside from sodium‑glucose cotransporter‑2 (SGLT2) inhibitors?

GLP-1 Receptor Agonists Are the Preferred Safe Option for Heart Failure and CKD Patients Besides SGLT2 Inhibitors

For patients with diabetes, heart failure, and chronic kidney disease who cannot use SGLT2 inhibitors, GLP-1 receptor agonists (specifically long-acting formulations with proven cardiovascular benefit) are the preferred and safest additional therapy, followed by metformin if eGFR ≥30 mL/min/1.73 m².

Primary Recommendation: GLP-1 Receptor Agonists

The KDIGO 2022 guidelines explicitly state that GLP-1 receptor agonists are the preferred additional drug therapy when SGLT2 inhibitors and metformin are insufficient or cannot be used 1. This preference is based on:

• Cardiovascular protection: GLP-1 RAs reduce major adverse cardiovascular events (MACE), with particularly strong benefits in patients with established cardiovascular disease 2
• Kidney protection: They reduce albuminuria and slow eGFR decline 2
• Heart failure safety: Unlike some other agents, GLP-1 RAs show neutral to favorable effects on heart failure outcomes 3, 4
• No hypoglycemia risk: When used without insulin or sulfonylureas 1

Specific GLP-1 RA Selection

Choose agents with documented cardiovascular benefit 1:

• Dulaglutide, liraglutide, or injectable semaglutide - these have demonstrated cardiovascular benefits in outcome trials 2
• Most require no dose adjustment across CKD stages 3-4 2
• Avoid exenatide once-weekly and lixisenatide in advanced CKD (eGFR <30) 2

Secondary Option: Metformin

Metformin remains safe and recommended if eGFR ≥30 mL/min/1.73 m² 1, 2:

Dosing Algorithm by Kidney Function:

• eGFR ≥60: Full dose (up to 2000 mg/day)
• eGFR 45-59: Continue full dose, but consider reduction in high-risk patients
• eGFR 30-44: Reduce to maximum 1000 mg/day 2
• eGFR <30: Discontinue - contraindicated 1, 2

Critical monitoring: Check eGFR every 3-6 months when <60, and monitor vitamin B12 after 4 years of use 1

Additional Safe Options (Third-Line)

When GLP-1 RAs and metformin are insufficient or contraindicated, the following are considered safe in heart failure with CKD 1, 5:

DPP-4 Inhibitors

• Generally neutral on heart failure outcomes 3, 4
• Linagliptin: No dose adjustment needed across all CKD stages - most convenient option 2
• AVOID saxagliptin - associated with increased heart failure hospitalization 4, 6
• Sitagliptin and alogliptin require dose reduction in CKD 2

Insulin

• Safe but requires conservative titration to avoid hypoglycemia, which is increased in CKD 1, 7
• Neutral effect on heart failure 3, 4
• Clearance is reduced in CKD, necessitating dose reductions 7

Medications to AVOID in Heart Failure

Absolutely Contraindicated:

• Thiazolidinediones (pioglitazone, rosiglitazone): Cause fluid retention and exacerbate heart failure - contraindicated in NYHA class III-IV 1, 3, 4, 6

Use with Extreme Caution:

• Sulfonylureas: While not contraindicated, they carry significant hypoglycemia risk in CKD and may cause weight gain 1, 7. If used, prefer glipizide or gliclazide (no active metabolites); avoid glyburide 7
• Alpha-glucosidase inhibitors: Contraindicated if eGFR <30 2

Practical Implementation Algorithm

Step 1: If patient cannot use SGLT2i → Start long-acting GLP-1 RA (dulaglutide, liraglutide, or semaglutide)

Step 2: Ensure metformin is optimized if eGFR ≥30 (dose-adjust per algorithm above)

Step 3: If additional glucose lowering needed → Add linagliptin (DPP-4i with no dose adjustment)

Step 4: If still inadequate control → Add basal insulin with conservative titration

Step 5: Monitor closely for:

• Volume status (GLP-1 RAs can cause GI side effects affecting hydration)
• Hypoglycemia risk (especially if combining with insulin)
• eGFR changes (adjust metformin accordingly)
• Heart failure symptoms (any worsening should prompt medication review)

Critical Pitfalls to Avoid

1. Never use thiazolidinediones in any patient with heart failure
2. Never use saxagliptin - specific DPP-4i with heart failure risk
3. Do not continue metformin if eGFR drops <30
4. Avoid sulfonylureas unless absolutely necessary - high hypoglycemia risk in CKD
5. Do not assume all GLP-1 RAs are equal - choose those with proven cardiovascular benefit

This approach prioritizes organ protection and safety over pure glucose lowering, recognizing that cardiovascular and kidney outcomes matter more than HbA1c targets in this high-risk population 1, 2.